Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00557856 · ClinicalTrials.gov registry record · Phase 1
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 10
- Study locations
NCT00557856: Completed Phase 1 study of Advanced Solid Tumors, sponsored by Pfizer.
NCT00557856 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 70 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (65% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00557856, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize). New treatments aimed at preventing these blood vessels have the ability to improve the clinical management of cancer.
Primary Outcome
MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT and at least 2 out of 3/6 participants in the next higher dose. DLT was defined as any of the following events occurring during the first 42 days of study drug: any grade greater than or equal to 3 hematologic and non-hematologic toxicity, all non-disease-related adverse events (AEs).
Conditions Studied
Interventions
- DRUG PF-03446962
Study Locations (10)
Other
- S.C Diagnostica Radiologica 2 - Milan
- S.C. Chirurgia Generale Indirizzo Oncologico 1 (epato-gastro-pancreatica) - Milan
- S.C. Medicina Oncologica I, Fondazione IRCCS Istituto Nazionale Tumori - Milan
- Dipartimento di Medicina - Milan
- UO di Oncologia ed Ematologia, Istituto Clinico Humanitas-Humanitas Cancer Center - Rozzano (MI)
- Seoul National University Hospital / Department of Internal Medicine - Seoul
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
- Vanderbilt University Medical Center - Nashville
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
South Carolina
- Medical University of South Carolina, Hollings Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
What the finished NCT00557856 record still lists
NCT00557856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PF-03446962 is the first listed.
NCT00557856 lists 10 locations in 4 states (Other, Tennessee, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00557856 about?
NCT00557856 is a clinical study titled "A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors". The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize). New treatments aimed at preventing these blood vessels have the ability to improve the clinica...
What is the current status of trial NCT00557856?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2007-11. Estimated completion is 2013-03.
What conditions does trial NCT00557856 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT00557856?
The interventions under investigation include: PF-03446962 (DRUG).
Who is sponsoring clinical trial NCT00557856?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00557856 being conducted?
This trial has 10 study locations across Pennsylvania, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00557856's enrollment target sits among peer trials
70 93rd of 144 higher than 52 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia